Cheson on Oncology

 
 
  • A Challenger to Interim PET in Lymphoma   Dr. Bruce Cheson reports on recent data suggesting that measurement of metabolic tumor volume and total lesion glycolysis may be a better predictor of outcome in lymphoma than interim PET scanning.
  • Follicular Lymphoma: Watch and Wait for Better Therapies?   Dr. Bruce Cheson comments on the significance of 2 studies that show no survival advantage between watchful waiting and treatment in patients with early follicular lymphoma.
  • Lance Armstrong: Still a Champion   Dr. Bruce Cheson, an avid cyclist, weighs in on the controversy surrounding Lance Armstrong's doping allegations, his long fight against the USADA, and what could prove to be his more lasting legacy.
  • Why the Holdup on New Combo Therapies in Lymphoma?   Clinical trials to test combinations of therapies in Hodgkin lymphoma have hit bureaucratic bottlenecks, much to the frustration of Dr. Bruce Cheson.
  • Best Regimens for Lymphoma Patients With Bad Hearts   Dr. Bruce Cheson reports the best evidence on treatment options available for lymphoma patients who have cardiac impairment.
  • Carfilzomib Approval Ready -- or Not?   Recently the FDA Advisory Committee recommended accelerated approval for use of carfilzomib in refractory multiple myeloma, but Dr. Bruce Cheson challenges the strength of the supporting evidence.
  • Blood Cancers: What to Look for in Leukemia   Dr. Bruce Cheson highlights noteworthy studies, new drugs, and impressive data in ALL, CLL, and CML that will be discussed at ASCO® 2012.
  • Blood Cancers: Lymphoma, Myeloma Preview   Dr. Bruce Cheson previews studies to be presented at ASCO® 2012 that will change or confirm therapies in follicular lymphoma, Hodgkin lymphoma, myeloma, and more.
  • Another 'CLL Case' Cured   Dr. Bruce Cheson discusses a patient referral that serves as a reminder that healthy persons can harbor markers of disease when no disease is present.
  • When Patients Think They Know Best   Dr. Bruce Cheson reports on 2 patients with Hodgkin lymphoma: one who wants more therapy, the other less. When patients think they know best, how can docs convince them of the right therapy?
  • Why Your Journal Submission Was Rejected   Dr. Bruce Cheson provides insider advice that will up your chances of having your submissions to medical journals accepted for publication.
  • Steve Jobs: One More Thing   Dr. Bruce Cheson comments on Walter Isaacson's biography Steve Jobs, finding a poignant lesson in the life and death of the entrepreneur whom the author calls a 'magician genius.'
  • Doc Takes Issue With Public Views of EMR   Comments posted to a New York Times article about electronic medical records prompt Dr. Bruce Cheson to assess the pros and cons of EMRs.
  • Drug Shortages: A Situation Going to the Dogs   The US drug shortage is affecting patient care and survival, clinical research, and now canine health. Dr. Bruce Cheson reports on the situation.
  • Star Wars in the Empire of All Maladies   Dr. Bruce Cheson and his fellows discuss The Emperor of All Maladies, Siddhartha Mukherjee’s book about the history of cancer, and pick the investigators whose contributions they find most compelling.
  • Do Unpublished Data Need an Expiration Date?   Dr. Bruce Cheson says that study data can be updated for years at meetings before the results are published. Should there be a limit to such updating to prevent premature data from dying on the vine?
  • Brentuximab: Effective but Use With Care!   Dr. Bruce Cheson discusses precautions to be observed when using brentuximab vedotin to treat lymphoma patients, in light of an FDA warning that its use carries risk for a rare but serious brain infection.
  • Radioimmunotherapy: How Strong an Option Is It?   Dr. Bruce Cheson reviews recent and older studies to assess how strong a treatment option radioimmunotherapy is for patients with follicular lymphoma.
  • Radiation Therapy vs Chemo in Hodgkin Lymphoma Patients   Dr. Bruce Cheson reports on a controversial study presented at the 2011 ASH meeting that compares survival after radiation therapy vs after ABVD chemo in patients with limited HL.
  • Reason to RESORT to Rituximab Maintenance?   Dr. Bruce Cheson reviews the RESORT study, which addresses the controversial issue of rituximab maintenance therapy in patients with follicular lymphoma.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.